Understanding Ketamine's Approved Medical Uses and How It Is Regulated
Ketamine has a complex history that reflects its dual nature: a valued medication with recognized medical applications and a controlled substance subject to federal oversight. Over the past several decades, this dissociative anesthetic has moved from surgical operating rooms to clinics exploring its potential in mental health treatment. Understanding its approved uses and the regulatory framework that governs it is essential for anyone curious about modern pharmaceutical options and how the medical system balances therapeutic benefit against abuse risk.
While many people associate ketamine primarily with anesthesia, the landscape has broadened significantly. In particular, esketamine—a refined form approved by the FDA—now represents a new chapter in depression treatment. At the same time, the drug remains tightly controlled under federal law, with prescribing privileges limited to licensed medical professionals. This article explores both approved uses and the regulatory mechanisms that keep ketamine accessible to patients who need it while minimizing potential harms.
What Is Ketamine and How Does It Work
Ketamine is a general anesthetic developed in the 1960s and is used in medicine to relieve pain and has gained recent attention for its antidepressant effects. Pharmacologically, it's a dissociative anesthetic and an NMDA-receptor antagonist—a description of how the drug acts on the brain. Unlike typical pain relievers or antidepressants that work on different brain pathways, ketamine's mechanism offers a distinct therapeutic approach.
It has pain-relieving properties and produces dissociative effects among users. The dissociative properties—an altered sense of reality or detachment from one's body—are both a feature and a consideration in how the drug is managed clinically. Medical professionals can harness these effects when used appropriately, yet they also require careful supervision when ketamine is administered to patients.
Ketamine's Primary Approved Medical Use: Anesthesia
Ketamine is approved by the Food and Drug Administration (FDA) as a general anesthetic that can be used alone or in combination with other medicines to assist during and prior to surgeries. This remains its longest-established and most straightforward approved indication. Ketamine is FDA-approved as a general anesthetic to be used as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.
In surgical settings, ketamine is given as an intravenous injection (IV) or as an intramuscular injection (IM). Hospital anesthesiologists and surgical teams continue to rely on ketamine for its reliable anesthetic properties. Its use in this context is well-established and remains standard practice in operating rooms worldwide, particularly in emergency and resource-limited settings where other anesthetics may not be available.
Esketamine (Spravato): FDA Approval for Depression
In recent years, esketamine has emerged as a major development in psychiatric treatment. Initially approved in 2019 for treatment-resistant depression, Spravato is now cleared for use as a standalone treatment for major depressive disorder (MDD). This expansion represents a significant shift in how depression can be managed, particularly for patients who have not responded to conventional oral medications.
On January 21, 2025, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's nasal spray, Spravato® (esketamine), to be used as a standalone treatment for adults with treatment-resistant depression (TRD). This groundbreaking decision marks the first time a medication for TRD has been approved as a monotherapy, expanding its potential use beyond its previous indication, which required pairing with oral antidepressants.
SPRAVATO® (esketamine) is a nasal spray containing the S-enantiomer of ketamine, meaning it's derived from ketamine but uses a more potent molecular form. The FDA approval process for Spravato involved rigorous clinical trials demonstrating safety and efficacy in a population with severe, hard-to-treat depression.
How Spravato Differs From Other Forms
Spravato is distinct from other ketamine formulations. SPRAVATO® is esketamine nasal spray—FDA-approved specifically for treatment-resistant depression with insurance coverage through many plans. The nasal spray delivery method is unique to the FDA-approved formulation, and this matters for both efficacy and regulatory control. Other forms of ketamine—such as intravenous infusions—may be used off-label by clinicians in certain circumstances, but they do not carry specific FDA approval for depression treatment.
Regulatory Framework: Controlled Substance Scheduling
Ketamine's legal status stems from federal law, not just its medical properties. Ketamine is a DEA Schedule III controlled substance, indicating accepted medical use with moderate abuse potential. This scheduling was intentionally chosen to reflect both its medical value and its potential for misuse.
Ketamine has a potential for abuse less than the drugs or other substances in Schedules I and II. Ketamine has currently accepted medical use in treatment in the United States. Abuse of ketamine may lead to moderate or low physical dependence or high psychological dependence. Based on these findings, the Deputy Administrator of the DEA concludes that ketamine, including its salts and isomers, and salts of isomers, warrants control in Schedule III in the CSA.
The Schedule III designation means ketamine sits in a middle tier of federal control. Schedule I drugs, like heroin, are defined as having no accepted medical use and the highest abuse potential — they cannot be legally prescribed at all under federal law. Schedule II drugs, including oxycodone, fentanyl, and Adderall, have an accepted medical use but also a high abuse potential and a real risk of severe psychological or physical dependence, so they come with the tightest prescribing controls short of an outright ban. Schedule III sits below both of those: an accepted medical use, a moderate to low potential for physical dependence, but still enough psychological dependence potential and misuse history to require a prescription and DEA tracking.
How Ketamine Prescribing and Distribution Is Controlled
As a Schedule III drug, ketamine can only be manufactured, distributed, and dispensed by DEA-registered practitioners and pharmacies. Prescriptions are subject to standard controlled-substance rules, including refill limits and record-keeping requirements. These regulations ensure that ketamine remains accessible to medical professionals while creating barriers to unauthorized use.
For Spravato specifically, additional safeguards apply beyond standard Schedule III controls. Spravato is administered only in certified healthcare settings under the REMS program—patients must be monitored for at least 2 hours post-dose due to risks of sedation and dissociation. The REMS (Risk Evaluation and Mitigation Strategy) program is a heightened safety framework that the FDA uses when a drug carries significant risks requiring careful oversight.
This combination of scheduling and REMS requirements means that patients cannot simply fill a Spravato prescription at a pharmacy and take it home. Instead, they must visit a certified clinic, receive the medication under supervision, and be monitored before leaving. This structure protects patients and reinforces the clinical nature of esketamine treatment.
Comparison of Approved Uses and Delivery Methods
| Use | Form | FDA Status | Setting | Monitoring |
|---|---|---|---|---|
| Surgical anesthesia | IV or IM injection | Approved (long-standing) | Operating room, hospital | Anesthesiology team |
| Treatment-resistant depression | Esketamine nasal spray (Spravato) | Approved (monotherapy as of 2025) | Certified healthcare clinic | Post-dose observation minimum 2 hours |
| Depression, pain, anxiety (off-label) | IV infusion | Not FDA-approved; used off-label | Specialty clinics | Variable by clinic |
Compounded Ketamine: Regulatory Gaps
It is important to understand that not all ketamine products carry FDA approval. The FDA does not confer approval for any compound drugs, including compounded ketamine products. Essentially, this means that the FDA has not verified "the safety, effectiveness or quality of compounded drugs before they are marketed." Since the FDA has not approved any compounded ketamine products, both prescribing providers and their patients must carefully assess the risks of using these products.
Compounded ketamine—made by pharmacies rather than manufactured by pharmaceutical companies—may be legally prescribed off-label for certain conditions, but it lacks the FDA's verification of quality and consistency. This distinction is crucial for patients considering various ketamine treatment options. The FDA-approved esketamine nasal spray offers regulatory assurance that the approved formulations do not.
Off-Label Use and Ongoing Research
The FDA has recognized that there has been significant interest in the use of ketamine for off-label conditions such as depression and chronic pain. Off-label use means that a medication approved for one purpose is prescribed for a different indication. This is legal when done by licensed practitioners, but it falls outside the FDA's formal approval process.
IV ketamine for depression, anxiety, PTSD, and chronic pain is off-label but legal when administered by licensed providers. Many clinics across the United States now offer ketamine infusions for mental health and pain conditions, relying on the physician's authority to prescribe medications off-label and on accumulated clinical experience. However, these uses do not carry the same regulatory backing as FDA-approved indications like Spravato or surgical anesthesia.
Key Takeaways About Ketamine Regulation and Approval 🔑
- 💊 Approved uses: Ketamine is FDA-approved as a general anesthetic for surgery and diagnostic procedures. Esketamine (Spravato) is FDA-approved for treatment-resistant depression as a nasal spray and as monotherapy.
- 💊 Controlled substance status: Ketamine is a Schedule III controlled substance, reflecting accepted medical use with moderate abuse potential and psychological dependence risk.
- 💊 Prescribing requirements: Only DEA-registered practitioners and pharmacies can dispense ketamine; prescriptions are tracked and refill limits apply.
- 💊 Safety oversight: Spravato requires administration in certified healthcare settings with post-dose monitoring and a REMS program for patient safety.
- 💊 Off-label use: Ketamine infusions for depression, anxiety, and pain are legal when prescribed by licensed medical professionals but lack specific FDA approval for these conditions.
- 💊 Compounded products: Compounded ketamine is not FDA-approved and lacks verification of quality; its safety profile is not established by the FDA.
Considerations for Patients and Providers
For anyone considering ketamine-based treatment, understanding the distinction between approved and off-label uses is important. FDA approval of Spravato for depression represents a formal determination that the drug is safe and effective for that specific purpose when used under specified conditions. Off-label IV ketamine clinics may offer real options for some patients, but the evidence base and regulatory oversight differ significantly from approved uses.
If you are interested in ketamine treatment for any condition, speaking with a qualified healthcare professional is essential. They can explain your options, discuss what is FDA-approved versus off-label, address any concerns about the Schedule III status and potential dependence, and help determine whether ketamine treatment is appropriate for your situation. The regulatory framework surrounding ketamine reflects both its therapeutic value and the need for careful, professional oversight—a balance designed to serve patients well.